• Mira Smart Conferencing
  • Home
  • Table of Contents
  • Advanced Search
 
Advanced Search

Browse All

Current Filters

CLEAR FILTER x

TITLE

Author Institution:

  • UCB Pharma, Monheim, Germany, Monheim, Germany

Filter

Partial Search: Partial searches may be entered manually by pressing enter in the filter input field.
Author Filter: Selecting one or more Authors from the Author drop down list will filter results by Author last name(s) only.

Displaying 1 - 4 of 4

  • Page:
  • 1

Efficacy of Rozanolixizumab in Generalized Myasthenia Gravis: Subgroup Analyses from the Randomized Phase 3 MycarinG Study

Author:Vu, Tuan   Druzdz, Artur   Grosskreutz, Julian   Habib, Ali A.   Kaminski, Henry J.   Mantegazza, Renato   Utsugisawa, Kimiaki   Vissing, John   Beau-Lejdstrom, Raphaelle   Boehnlein, Marion   Gasalla, Teresa   Grimson, Fiona   Tarancón, Thaïs   Bril, Vera   

Session Name:S5: Autoimmune Neurology: NMOSD and MG, A Focus on Treatment Trials  

Topic:Autoimmune Neurology  

Program Number:S5.007  

Author Institution:University of South Florida Morsani College of Medicine, Tampa, FL  Municipal Hospital Poznan, Poznan, Poland  University of Lübeck, Lübeck, Germany  University of California, Orange, CA  George Washington University, Washington, DC  Fondazione IRCCS, Istituto Nazionale Neurologico Carlo Besta, Milan, Italy  Hanamaki General Hospital, Hanamaki, Japan  Rigshospitalet, University of Copenhagen, Copenhagen, Denmark  UCB Pharma, Bulle, Switzerland, Bulle, Switzerland  UCB Pharma, Monheim, Germany, Monheim, Germany  UCB Pharma, Morrisville, NC, USA, Morrisville, NC  UCB Pharma, Slough, UK, Slough, United Kingdom  UCB Pharma, Madrid, Spain, Madrid, Spain  University Health Network, Toronto, ON, Canada  

  • View Abstract
  • View Disclosure

Subgroup outcomes from RAISE: A randomized, Phase 3 trial of zilucoplan in generalized myasthenia gravis

Author:Weiss, Michael D.   Bresch, Saskia   Freimer, Miriam   Hewamadduma, Channa   Juntas-Morales, Raul   Leite, M. Isabel   Maniaol, Angelina   Masuda, Masayuki   Sivakumar, Kumaraswamy   Zajda, Malgorzata   Boroojerdi, Babak   Duda, Petra W.   De La Borderie, Guillemette   Howard Jr., James F.   

Session Name:P1: Autoimmune Neurology: Myasthenia Gravis  

Topic:Autoimmune Neurology  

Program Number:P1.006  

Author Institution:University of Washington Medical Center, Department of Neurology, Seattle, WA  Centre Hospitalier Universitaire de Nice, Nice, France  The Ohio State University, Columbus, OH  University of Sheffield, Sheffield, United Kingdom  Vall d’Hebron University Hospital, Barcelona, Spain  Nuffield Department of Clinical Neurosciences - University of Oxford, Oxford, United Kingdom  Oslo University Hospital, Oslo, Norway  Tokyo Medical University, Tokyo, Japan  University of Arizona, School of Medicine, Neuromuscular Clinic and Research Center, Phoenix, AZ  Medical University of Warsaw, Warsaw, Poland  UCB Pharma, Monheim, Germany, Monheim, Germany  UCB Pharma, Cambridge, MA, USA, Cambridge, MA  UCB Pharma, Brussels, Belgium, Saint Cloud, France  The University of North Carolina, Chapel Hill, NC  

  • View Abstract
  • View Disclosure

RAISE-XT: An interim analysis of safety and efficacy in an open-label extension study of zilucoplan in patients with myasthenia gravis

Author:Freimer, Miriam   Leite, M. Isabel   Genge, Angela   Hussain, Yessar   Kaminski, Henry J.   Mantegazza, Renato   Utsugisawa, Kimiaki   Vu, Tuan   Duda, Petra W.   Boroojerdi, Babak   Vanderkelen, Mark   Lowcock, Romana   Howard Jr., James F.   

Session Name:P1: Autoimmune Neurology: Myasthenia Gravis  

Topic:Autoimmune Neurology  

Program Number:P1.007  

Author Institution:The Ohio State University Wexner Medical Center, Columbus, OH  University of Oxford, Oxford, United Kingdom  The Montreal Neurological Institute, Montreal, QC, Canada  The University of Texas at Austin, Austin, TX  George Washington University, Washington, DC  Fondazione Istituto Neurologico, Milan, Italy  Hanamaki General Hospital, Hanamaki, Japan  University of South Florida Morsani College of Medicine, Tampa, FL  UCB Pharma, Cambridge, MA, USA, Cambridge, MA  UCB Pharma, Monheim, Germany, Monheim, Germany  UCB Pharma, Braine L'Alleud, Belgium, Braine L'Alleud, Belgium  UCB Pharma, Slough, UK, Slough, United Kingdom  The University of North Carolina at Chapel Hill, Chapel Hill, NC  

  • View Abstract
  • View Disclosure

Long-term Efficacy and Safety of Symptom-driven Cyclic Rozanolixizumab Treatment in Patients with Generalized Myasthenia Gravis: A Pooled Analysis of a Phase 3 Study and Two Open-label Extension Studies

Author:Bril, Vera   Druzdz, Artur   Grosskreutz, Julian   Habib, Ali A.   Mantegazza, Renato   Utsugisawa, Kimiaki   Vissing, John   Vu, Tuan   Boehnlein, Marion   Gayfieva, Maryam   Greve, Bernhard   Woltering, Franz   Kaminski, Henry J.   

Session Name:P1: Autoimmune Neurology: Myasthenia Gravis  

Topic:Autoimmune Neurology  

Program Number:P1.012  

Author Institution:University Health Network, Toronto, ON, Canada  Municipal Hospital Poznan, Poznan, Poland  University of Lübeck, Lübeck, Germany  University of California, Irvine, Orange, CA  Fondazione IRCCS, Istituto Nazionale Neurologico Carlo Besta, Milan, Italy  Hanamaki General Hospital, Hanamaki, Japan  Rigshospitalet, University of Copenhagen, Copenhagen, Denmark  University of South Florida Morsani College of Medicine, Tampa, FL  UCB Pharma, Monheim, Germany, Monheim, Germany  UCB Pharma, Slough, UK, Slough, United Kingdom  UCB Pharma, Monheim, Germany, Monheim , Germany  George Washington University, Washington, DC  

  • View Abstract
  • View Disclosure

Displaying 1 - 4 of 4

  • Page:
  • 1

© 2015 Mira Smart Conference | http://www.mirasmart.com